Philip Morris: A Steady Hand in Shifting Fields

by

Philip Morris International (PM +0.47%) has begun this year with a quiet strength, a rise of thirteen percent against the current. It’s not a shout, not a boom, but the steady gain of a field well-tended. The earnings report, while not causing a stampede, revealed a company that understands the long rows, the changing seasons of consumer habits. A good stock, this, for those who plant for the harvest, not the quick bloom.

Let us look closer at the yield of this quarter, and what may come.

Loading widget...

The Smoke Fades, New Seedlings Rise

The company’s shift away from the old ways continues to bear fruit. The Zyn pouches, little packets of comfort, are gaining ground – shipments up eighteen percent, twenty percent within the States. The heated tobacco, the Iqos, is finding favor in Japan and Europe, spreading now to new lands. It’s a slow conversion, like turning a plow, but a necessary one. The traditional cigarettes, of course, are diminishing, falling by a little over two percent. It’s the way of things; the old yields less with each passing year.

Overall, the company’s earnings rose by nearly four percent, reaching ten and a half billion dollars. A solid return, not extravagant, but honest. Adjusted earnings per share climbed to one dollar and seventy cents, a gain of almost ten percent. A reasonable bounty for a year’s work.

Looking ahead, Philip Morris expects continued growth, a rise of five to seven percent in revenue. The industry as a whole, excluding China and the United States, is expected to decline slightly, but the company hopes to offset this with gains elsewhere. Cigarette volumes will likely fall, burdened by taxes in Mexico and India, but a recovery is anticipated in Turkey. The smoke-free alternatives, however, are expected to flourish, growing by a healthy eight to ten percent.

The company projects earnings per share between eight dollars and thirty-eight cents and eight dollars and fifty-three cents, a growth of eleven to thirteen percent. Excluding currency fluctuations, the range is slightly narrower, eight dollars and eleven cents to eight dollars and twenty-six cents, representing a growth of seven and a half to nine and a half percent. It’s not a fortune, but it’s a living, a steady income in a restless world.

Over the next three years, Philip Morris anticipates generating forty-five billion dollars in operating cash flow. They foresee acceleration in 2027, aided by the easing of tax burdens in Japan and the potential introduction of Iqos in the United States, pending regulatory approval. They are also preparing to launch Zyn Ultra, a stronger, more flavorful version, awaiting the nod from the FDA. It’s a calculated gamble, a planting of new seeds, hoping for a richer harvest.

A Time to Consider

Despite the shifting winds, Philip Morris International appears poised for continued, if measured, growth. The company possesses a certain pricing power, a resilience born of years in the field. The Zyn Ultra offers a potential boost, and the eventual introduction of Iqos in the U.S. could be a significant opportunity.

The stock currently trades at a forward price-to-earnings ratio of under twenty-two, based on analyst estimates. It’s a reasonable valuation for a company that combines growth with a degree of defensiveness. A good stock to hold, to nurture, for those who understand that the long rows often yield the most substantial rewards.

Read More

2026-02-11 16:03